Skip to main content

Table 2 CD4+ T cell subsets proportion in primary HIV infection before and after initiation of cART

From: Immune recovery in acute and chronic HIV infection and the impact of thymic stromal lymphopoietin

  

Primary HIV (PHI)

Chronic patients CD4 < 200 (LP-AD)

Chronic patients CD4 200–350 (LP-nonAD)

Chronic patients CD4 > 350 (EP)

P*

N = 14

N = 20

N = 24

N = 42

Cells/μL

CD4

 Baseline

550 (327)a,b

55.5 (110)a

290 (97)b

510 (172)

< .001

 After 6 months of cART

740 (375)a,b

210 (280)a

450 (190)b

690 (265)

< .001

 After 12 months of cART

720 (435)a,b

340 (170)a

505 (198)b

740 (210)

< .001

 After 24 months of cART

680 (240)a

269 (160)a

695 (290)

820 (317)

< .001

% CD4 Cells

RTE

 Baseline

14 (11)

11 (16)

20 (15)

18 (14)

.063

 After 6 months of cART

16 (11)b

8 (18)

27 (15)b

19 (15)

.006

 After 12 months of cART

8 (17)

6 (20)

17 (25)

5 (25)

.588

 After 24 months of cART

18 (9)b

17 (10)

28 (11)b

17 (16)

.009

Naive

 Baseline

43 (20)a

23 (30)a

40 (26)

44 (21)

< .001

 After 6 months of cART

37 (23)

22 (31)

49 (19)

39 (20)

.031

 After 12 months of cART

46 (30)

28 (28)

49 (19)

45 (24)

.066

 After 24 months of cART

36 (12)b

30 (16)

55 (16)b

37 (15)

.002

EM

 Baseline

12 (7)

17 (14)

16 (12)

12 (6)

.009

 After 6 months of cART

7 (4)a

18 (11)a

6 (4)

7 (4)

.001

 After 12 months of cART

9 (6)a

15 (14)a

7 (5)

6 (3)

.007

 After 24 months of cART

9 (4)a

15 (6)a

6 (7)

7 (5)

.043

CM

 Baseline

26 (6)

20 (22)

24 (10)

24 (10)

.597

 After 6 months of cART

29 (11)

35 (18)

27 (15)

28 (14)

.969

 After 12 months of cART

26 (8)

24 (16)

24 (11)

25 (10)

.949

 After 24 months of cART

24 (14)

30 (23)

24 (8)

32 (16)

.784

LD

 Baseline

5 (4)b

3 (12)

1 (2)b

5 (8)

.009

 After 6 months of cART

8 (11)b

3 (8)

1 (3)b

5 (7)

.012

 After 12 months of cART

7 (14)

4 (11)

2 (3)

7 (12)

.126

 After 24 months of cART

9 (16)a,b

1 (1)a

3 (2)b

9 (13)

.038

  1. Data are presented as median and (IQR)
  2. Abbreviations: LP-AD late presenters with advanced disease, LP-nonAD late presenters without advanced disease, EP early presenters, PHI primary HIV infection
  3. P*: comparing the four HIV groups by using Kruskal-Wallis test. If significant (<0.05) then Mann-Whitney was used to compare PHI group with the other chronic groups. Only significant differences are marked: aPHI vs LP-AD; bPHI vs LP-nonAD; cPHI vs EP
  4. Significant P values are shown in bold